


## Visible Light-Activatable Platinum(IV) Prodrugs Harnessing CD36 for Ovarian Cancer Therapy


Amarasooriya M. D. S. Jayawardhana,<sup>a</sup> Srijana Bhandari,<sup>a</sup> Ariela W. Kaspi-Kaneti,<sup>b</sup> Man Kshetri,<sup>a</sup> Zihan Qiu,<sup>a</sup> May Cheline,<sup>a</sup> Hao Shen,<sup>a</sup> Barry Dunitz,<sup>a</sup> and Yao-Rong Zheng<sup>a,a</sup>

a. Department of Chemistry and Biochemistry, Kent State University, Kent, OH 44242.


b. University of La Verne, 1950 3rd Street, La Verne, CA 91750




**Fig S1.** Synthesis and characterization of the photoactivatable Pt (IV) prodrug (**1**): **A**. Synthetic route for preparing the Pt(IV) prodrug; **B**. <sup>1</sup>H NMR spectrum in DMSO-d<sub>6</sub>; **C**. <sup>13</sup>C NMR spectrum in DMSO-d<sub>6</sub>; **D**. High resolution ESI-MS spectrum; **E**. Analytic HPLC analysis (Gradient: 0 min 5% B, 5 min 5% B, 12 min 95% B, 15 min 95% B, 18 min 5% B. solvent A is 0.1% TFA aqueous solution and B is acetonitrile).




**Fig S2.** Cellular uptake of **1** ([Pt] = 10  $\mu$ M, 4 h) against the A2780cis cells without (*left*) and with (*right*) the pre-treatment of SSO (200  $\mu$ M, 0.5 h).



**Fig S3.** Flow cytometric analysis of cell death of the A2780cis cells treated with **1** (20  $\mu$ M, 6 h) in the absence (Dark) or presence (490 nm) of 20-min irradiation by 490 nm light (2.36 mW/cm<sup>2</sup>).



Fluorescein only  
(-4232.7498058473H)



Compound 1  
(-4232.7498058473H)

**Fig S4.** Optimized ground state geometries and respective energies of fluorescein and Compound 1.